Mosca, Mirta; Conci, Nicole; Di Federico, Alessandro; Tateo, Valentina; Favorito, Valentina; Zappi, Arianna; Gelsomino, Francesco; De Giglio, Andrea, First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis, «JCO PRECISION ONCOLOGY», 2023, 7, pp. 1 - 16 [Scientific article]
Alessi J.V.; Wang X.; Elkrief A.; Ricciuti B.; Li Y.Y.; Gupta H.; Spurr L.F.; Rizvi H.; Luo J.; Pecci F.; Lamberti G.; Recondo G.; Venkatraman D.; Di Federico A.; Gandhi M.M.; Vaz V.R.; Nishino M.; Sholl L.M.; Cherniack A.D.; Ladanyi M.; Price A.; Richards A.L.; Donoghue M.; Lindsay J.; Sharma B.; Turner M.M.; Pfaff K.L.; Felt K.D.; Rodig S.J.; Lin X.; Meyerson M.L.; Johnson B.E.; Christiani D.C.; Schoenfeld A.J.; Awad M.M., Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC, «JOURNAL OF THORACIC ONCOLOGY», 2023, 18, pp. 1524 - 1537 [Scientific article]
Alessi J.V.; Ricciuti B.; Wang X.; Pecci F.; Di Federico A.; Lamberti G.; Elkrief A.; Rodig S.J.; Lebow E.S.; Eicholz J.E.; Thor M.; Rimner A.; Schoenfeld A.J.; Chaft J.E.; Johnson B.E.; Gomez D.R.; Awad M.M.; Shaverdian N., Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC, «NATURE COMMUNICATIONS», 2023, 14, Article number: 4238 , pp. 1 - 12 [Scientific article]Open Access
Mosca M.; Nigro M.C.; Pagani R.; De Giglio A.; Di Federico A., Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond, «BIOMOLECULES», 2023, 13, Article number: 1803 , pp. 1 - 15 [Scientific article]Open Access
Rossi S.; Gelsomino F.; Rinaldi R.; Muccioli L.; Comito F.; Di Federico A.; De Giglio A.; Lamberti G.; Andrini E.; Mollica V.; D'Angelo R.; Baccari F.; Zenesini C.; Madia P.; Raschi E.; Cortelli P.; Ardizzoni A.; Guarino M., Peripheral nervous system adverse events associated with immune checkpoint inhibitors, «JOURNAL OF NEUROLOGY», 2023, 270, pp. 2975 - 2986 [Scientific article]Open Access
Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea, Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis, «JOURNAL OF THE NATIONAL CANCER INSTITUTE», 2023, 115, pp. 29 - 42 [Scientific article]
Di Federico A.; Ricciotti I.; Favorito V.; Michelina S.V.; Scaparone P.; Metro G.; De Giglio A.; Pecci F.; Lamberti G.; Ambrogio C.; Ricciuti B., Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer, «CURRENT ONCOLOGY REPORTS», 2023, 25, pp. 1017 - 1029 [Scientific article]
Palloni, Andrea; Bisello, Silvia; Maggio, Ilaria; Massucci, Maria; Galuppi, Andrea; Di Federico, Alessandro; Rizzo, Alessandro; Ricci, Angela Dalia; Siepe, Giambattista; Morganti, Alessio Giuseppe; Brandi, Giovanni; Frega, Giorgio, The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma, «CURRENT ONCOLOGY», 2023, 30, pp. 4754 - 4766 [Scientific article]Open Access
Ricciuti B.; Elkrief A.; Alessi J.; Wang X.; Li Y.; Gupta H.; Muldoon D.M.; Bertram A.A.; Pecci F.; Lamberti G.; Di Federico A.; Barrichello A.; Vaz V.R.; Gandhi M.; Lee E.; Shapiro G.I.; Park H.; Nishino M.; Lindsay J.; Felt K.D.; Sharma B.; Cherniack A.D.; Rodig S.; Gomez D.R.; Shaverdian N.; Rakaee M.; Bandlamudi C.; Ladanyi M.; Janne P.A.; Schoenfeld A.J.; Sholl L.M.; Awad M.M.; Cheng M.L., Title: Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer, «CLINICAL CANCER RESEARCH», 2023, 29, pp. 2540 - 2550 [Scientific article]
Metro G.; De Giglio A.; Ricciuti B.; Siringo M.; Marinelli D.; Gelibter A.; Pecci F.; Berardi R.; Cantini L.; Di Federico A.; Andrini E.; Mosca M.; Lamberti G.; Brambilla M.; Mountzios G., Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease, «DRUGS IN CONTEXT», 2022, 11, Article number: A1 , pp. 1 - 10 [Scientific article]
De Giglio A.; Di Federico A.; Deiana C.; Ricciuti B.; Brambilla M.; Metro G., Advanced non-small-cell lung cancer: how to manage non-oncogene disease, «DRUGS IN CONTEXT», 2022, 11, Article number: 2022-2-4 , pp. 1 - 14 [Scientific article]Open Access
Carloni, Riccardo; Rizzo, Alessandro; Cusmai, Antonio; Palloni, Andrea; Federico, Alessandro Di; Marco, Mariacristina Di; Massafra, Raffaella; Fanizzi, Annarita; Palmiotti, Gennaro; Brandi, Giovanni, Advances in Novel Systemic Therapies for Advanced Hepatocellular Carcinoma, «FUTURE MEDICINAL CHEMISTRY», 2022, 14, pp. 1455 - 1470 [Scientific article]
Di Federico A.; Rizzo A.; Carloni R.; De Giglio A.; Bruno R.; Ricci D.; Brandi G., Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials, «EXPERT OPINION ON INVESTIGATIONAL DRUGS», 2022, 31, pp. 361 - 369 [Scientific article]
Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, Andrea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola, Giovanni Brandi, Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?, «FUTURE ONCOLOGY», 2022, 905, pp. 1 - 12 [Scientific article]
Di Federico, Alessandro; Filetti, Marco; Palladini, Arianna; Giusti, Raffaele; Piras, Marta; De Giglio, Andrea; Ardizzoni, Andrea; Gelsomino, Francesco, EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature, «TRANSLATIONAL LUNG CANCER RESEARCH», 2022, 11, pp. 497 - 503 [Scientific article]Open Access
